Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: France,Belgium,Norway,Austria,Switzerland,Italy,Ireland,Greece,United Kingdom,Spain
nct
Update Il y a 5 ans
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study: - Subjects who failed another TNF inhibitor (etanercept, infliximab) - Subjects with advanced spinal ankylosis - Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)
Country
Austria
,
Belgium
,
Denmark
,
Finland
,
France
,
Germany
,
Greece
,
Ireland
,
Italy
,
Netherlands
,
Norway
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
organs
None
Specialty
None
Closed trial
More information
1